Efficacy and Safety of Radiofrequency and Ethanol Ablation for Treating Locally Recurrent Thyroid Cancer: A Systematic Review and Meta-Analysis
Abstract
Background: The aim of this study was to evaluate the efficacy and safety of radiofrequency ablation (RFA) and ethanol ablation (EA) for treating locally recurrent thyroid cancer.
Materials and Methods: Ovid-MEDLINE and EMBASE databases were searched for studies on the efficacy and safety of RFA and EA for treating locally recurrent thyroid cancer. The pooled proportions of the volume reduction ratio (VRR) ≥50%, complete disappearance, changes in serum level of thyroglobulin (Tg), recurrence, and complications were assessed using random-effects modeling. Heterogeneity among studies was determined using the chi-square statistic for the pooled estimates and the inconsistency index I2. To overcome heterogeneity, sensitivity analysis was performed.
Results: Ten eligible studies were included, with a total sample size of 270 patients and 415 thyroid nodules. The pooled proportion of VRR ≥50% after RFA (100%, recalculated 100%; I2 = 100%, recalculated I2 = 55.3%) was higher than that after EA (89.5%; I2 = 82.4%; p = 0.2764); the pooled proportion of complete disappearance after RFA (68.8%) was higher than that after EA (53.4%; p = 0.3384); and the pooled proportion of recurrence after RFA (0.0%) was lower than that after EA (2.4%, adjusted 1.6%; p = 0.9766). However, these differences were not statistically significant. In addition, the pooled proportion of reduction in serum level of Tg after RFA was 71.6% and after EA was 93.8% (p < 0.0001). The pooled proportion of complications of both RFA (5.8%, adjusted 1.6%) and EA (1.6%) were low (p = 0.8479). The mean number of RFA sessions was <1.3 in five of six RFA studies, and the number of EA sessions was more than two in three of four EA studies.
Conclusion: Both RFA and EA are acceptable treatment modalities to manage locally recurrent thyroid cancer in terms of efficacy and safety for poor surgical candidates or those who refuse surgery.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Siegel R, Ma J, Zou Z, Jemal A 2014 Cancer statistics, 2014. CA Cancer J Clin 64:9–29.
2.
Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V 1992 Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164:658–661.
3.
Cady B, Rossi R 1988 An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953.
4.
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057; discussion 1057–1058.
5.
Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714–720.
6.
Baek JH, Kim YS, Sung JY, Choi H, Lee JH 2011 Locoregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ablation. AJR Am J Roentgenol 197:W331–336.
7.
Park KW, Shin JH, Han BK, Ko EY, Chung JH 2011 Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol 18:2564–2568.
8.
Guenette JP, Monchik JM, Dupuy DE 2013 Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J Vasc Interv Radiol 24:672–679.
9.
Lee SJ, Jung SL, Kim BS, Ahn KJ, Choi HS, Lim DJ, Kim MH, Bae JS, Kim MS, Jung CK, Chong SM 2014 Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma. Korean J Radiol 15:817–826.
10.
Wang L, Ge M, Xu D, Chen L, Qian C, Shi K, Liu J, Chen Y 2014 Ultrasonography-guided percutaneous radiofrequency ablation for cervical lymph node metastasis from thyroid carcinoma. J Cancer Res Ther 10:C144–149.
11.
Kim JH, Yoo WS, Park YJ, Park DJ, Yun TJ, Choi SH, Sohn CH, Lee KE, Sung MW, Youn YK, Kim KH, Cho BY 2015 Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. Radiology 276:909–918.
12.
Lim HK, Baek JH, Lee JH, Kim WB, Kim TY, Shong YK, Hong SJ 2015 Efficacy and safety of radiofrequency ablation for treating locoregional recurrence from papillary thyroid cancer. Eur Radiol 25:163–170.
13.
Kim BM, Kim MJ, Kim EK, Park SI, Park CS, Chung WY 2008 Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection. Eur Radiol 18:835–842.
14.
Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Grøholt KK, Berner A, Bjøro T, Jørgensen LH 2011 Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 96:2750–2755.
15.
Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW 2013 Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 154:1448–1454; discussion 1454–1445.
16.
Mauri G, Cova L, Tondolo T, Ierace T, Baroli A, Di Mauro E, Pacella CM, Goldberg SN, Solbiati L 2013 Percutaneous laser ablation of metastatic lymph nodes in the neck from papillary thyroid carcinoma: preliminary results. J Clin Endocrinol Metab 98:E1203–1207.
17.
Papini E, Bizzarri G, Bianchini A, Valle D, Misischi I, Guglielmi R, Salvatori M, Solbiati L, Crescenzi A, Pacella CM, Gharib H 2013 Percutaneous ultrasound-guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin Endocrinol Metab 98:E92–97.
18.
Fontenot TE, Deniwar A, Bhatia P, Al-Qurayshi Z, Randolph GW, Kandil E 2015 Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol Head Neck Surg 141:512–518.
19.
Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, Kim EK, Lee JH, Kim DW, Park JS, Kim KS, Baek SM, Lee Y, Chong S, Sim JS, Huh JY, Bae JI, Kim KT, Han SY, Bae MY, Kim YS, Baek JH 2012 Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 13:117–125.
20.
Lee YH, Baek JH, Jung SL, Kwak JY, Kim JH, Shin JH 2015 Ultrasound-guided fine needle aspiration of thyroid nodules: a consensus statement by the Korean Society of Thyroid Radiology. Korean J Radiol 16:391–401.
21.
Na DK, Choi YJ, Choi SH, Kook SH, Park HJ 2015 Evaluation of cervical lymph node metastasis in thyroid cancer patients using real-time CT-navigated ultrasonography: preliminary study. Ultrasonography 34:39–44.
22.
Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J 2003 The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25.
23.
Kim KW, Lee J, Choi SH, Huh J, Park SH 2015 Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—Part I. General guidance and tips. Korean J Radiol 16:1175–1187.
24.
Lee J, Kim KW, Choi SH, Huh J, Park SH 2015 Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—Part II. Statistical methods of meta-analysis. Korean J Radiol 16:1188–1196.
25.
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available at: http://handbook.cochrane.org/chapter_9/9_5_2_ identifying_and_measuring_heterogeneity.htm. Updated March 2011 (accessed August 15, 2015).
26.
Egger M, Davey Smith G, Schneider M, Minder C 1997 Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634.
27.
Duval S, Tweedie R 2000 Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463.
28.
Sohn YM, Hong SW, Kim EK, Kim MJ, Moon HJ, Kim SJ, Son EJ, Kwak JY 2009 Complete eradication of metastatic lymph node after percutaneous ethanol injection therapy: pathologic correlation. Thyroid 19:317–319.
29.
Dupuy DE, Monchik JM, Decrea C, Pisharodi L 2001 Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 130:971–977.
30.
Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR 2002 Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 178:699–704.
31.
Monchik JM, Donatini G, Iannuccilli J, Dupuy DE 2006 Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 244:296–304.
32.
Lim CY, Yun JS, Lee J, Nam KH, Chung WY, Park CS 2007 Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. Thyroid 17:347–350.
33.
Ha EJ, Baek JH, Lee JH 2014 Moving-shot versus fixed electrode techniques for radiofrequency ablation: comparison in an ex-vivo bovine liver tissue model. Korean J Radiol 15:836–843.
34.
Ha EJ, Baek JH, Lee JH 2015 Ultrasonography-based thyroidal and perithyroidal anatomy and its clinical significance. Korean J Radiol 16:749–766.
35.
Shin JE, Baek JH, Lee JH 2013 Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 25:14–19.
36.
Shin JH, Baek JH, Ha EJ, Lee JH 2012 Radiofrequency ablation of thyroid nodules: basic principles and clinical application. Int J Endocrinol 2012:919650.
37.
Hong MJ, Baek JH, Kim DY, Ha EJ, Choi WJ, Choi YJ, Lee JH 2014 Spinal accessory nerve: ultrasound findings and correlations with neck lymph node levels. Ultraschall Med 2014 Dec 17 [Epub ahead of print].
38.
Shin JE, Baek JH, Ha EJ, Choi YJ, Choi WJ, Lee JH 2015 Ultrasound features of middle cervical sympathetic ganglion. Clin J Pain 31:909–913.
39.
Pacella CM, Papini E 2013 Image-guided percutaneous ablation therapies for local recurrences of thyroid tumors. J Endocrinol Invest 36:61–70.
40.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D 2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700.
41.
The Cochrane Collaboration 2013 Handbook for Diagnostic Test Accuracy Reviews. The Cochrane Collaboration, London.
Information & Authors
Information
Published In
Copyright
Copyright 2016, Mary Ann Liebert, Inc.
History
Published online: 15 March 2016
Published in print: March 2016
Published ahead of print: 10 February 2016
Published ahead of production: 18 January 2016
Topics
Authors
Author Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.